These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 24300419)

  • 21. Identification of novel target genes of nerve growth factor (NGF) in human mastocytoma cell line (HMC-1 (V560G c-Kit)) by transcriptome analysis.
    Dutta P; Koch A; Breyer B; Schneider H; Dittrich-Breiholz O; Kracht M; Tamura T
    BMC Genomics; 2011 Apr; 12():196. PubMed ID: 21501463
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Kit inhibitor APcK110 induces apoptosis and inhibits proliferation of acute myeloid leukemia cells.
    Faderl S; Pal A; Bornmann W; Albitar M; Maxwell D; Van Q; Peng Z; Harris D; Liu Z; Hazan-Halevy I; Kantarjian HM; Estrov Z
    Cancer Res; 2009 May; 69(9):3910-7. PubMed ID: 19383925
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Regulation of cellular proliferation, cytoskeletal function, and signal transduction through CXCR4 and c-Kit in small cell lung cancer cells.
    Kijima T; Maulik G; Ma PC; Tibaldi EV; Turner RE; Rollins B; Sattler M; Johnson BE; Salgia R
    Cancer Res; 2002 Nov; 62(21):6304-11. PubMed ID: 12414661
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Imatinib inhibits proliferation of Ewing tumor cells mediated by the stem cell factor/KIT receptor pathway, and sensitizes cells to vincristine and doxorubicin-induced apoptosis.
    González I; Andreu EJ; Panizo A; Inogés S; Fontalba A; Fernández-Luna JL; Gaboli M; Sierrasesúmaga L; Martín-Algarra S; Pardo J; Prósper F; de Alava E
    Clin Cancer Res; 2004 Jan; 10(2):751-61. PubMed ID: 14760098
    [TBL] [Abstract][Full Text] [Related]  

  • 25. c-KIT signaling as the driving oncogenic event in sub-groups of melanomas.
    Smalley KS; Sondak VK; Weber JS
    Histol Histopathol; 2009 May; 24(5):643-50. PubMed ID: 19283671
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tyrosine kinase inhibitors induce down-regulation of c-Kit by targeting the ATP pocket.
    D'allard D; Gay J; Descarpentries C; Frisan E; Adam K; Verdier F; Floquet C; Dubreuil P; Lacombe C; Fontenay M; Mayeux P; Kosmider O
    PLoS One; 2013; 8(4):e60961. PubMed ID: 23637779
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Imatinib mesylate: in the treatment of gastrointestinal stromal tumours.
    Croom KF; Perry CM
    Drugs; 2003; 63(5):513-22; discussion 523-4. PubMed ID: 12600228
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term exposure to imatinib reduced cancer stem cell ability through induction of cell differentiation via activation of MAPK signaling in glioblastoma cells.
    Dong Y; Han Q; Zou Y; Deng Z; Lu X; Wang X; Zhang W; Jin H; Su J; Jiang T; Ren H
    Mol Cell Biochem; 2012 Nov; 370(1-2):89-102. PubMed ID: 22829019
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Toll-like receptors in the respiratory system: their roles in inflammation.
    Iwamura C; Nakayama T
    Curr Allergy Asthma Rep; 2008 Mar; 8(1):7-13. PubMed ID: 18377768
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor.
    Heinrich MC; Griffith DJ; Druker BJ; Wait CL; Ott KA; Zigler AJ
    Blood; 2000 Aug; 96(3):925-32. PubMed ID: 10910906
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Making a Notch in the lymphocyte kit.
    Rodewald HR
    Eur J Immunol; 2006 Mar; 36(3):508-11. PubMed ID: 16506288
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Constitutive activation of c-kit by the juxtamembrane but not the catalytic domain mutations is inhibited selectively by tyrosine kinase inhibitors STI571 and AG1296.
    Ueda S; Ikeda H; Mizuki M; Ishiko J; Matsumura I; Tanaka H; Shibayama H; Sugahara H; Takai E; Zhang X; Machii T; Kanakura Y
    Int J Hematol; 2002 Dec; 76(5):427-35. PubMed ID: 12512837
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Juxtamembrane mutant V560GKit is more sensitive to Imatinib (STI571) compared with wild-type c-kit whereas the kinase domain mutant D816VKit is resistant.
    Frost MJ; Ferrao PT; Hughes TP; Ashman LK
    Mol Cancer Ther; 2002 Oct; 1(12):1115-24. PubMed ID: 12481435
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Overexpression of the KIT/SCF in uveal melanoma does not translate into clinical efficacy of imatinib mesylate.
    Hofmann UB; Kauczok-Vetter CS; Houben R; Becker JC
    Clin Cancer Res; 2009 Jan; 15(1):324-9. PubMed ID: 19118061
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A juxtacrine/paracrine loop between C-Kit and stem cell factor promotes cancer stem cell survival in epithelial ovarian cancer.
    Mazzoldi EL; Pavan S; Pilotto G; Leone K; Pagotto A; Frezzini S; Nicoletto MO; Amadori A; Pastò A
    Cell Death Dis; 2019 May; 10(6):412. PubMed ID: 31138788
    [TBL] [Abstract][Full Text] [Related]  

  • 36. RabGEF1 regulates stem cell factor/c-Kit-mediated signaling events and biological responses in mast cells.
    Kalesnikoff J; Rios EJ; Chen CC; Nakae S; Zabel BA; Butcher EC; Tsai M; Tam SY; Galli SJ
    Proc Natl Acad Sci U S A; 2006 Feb; 103(8):2659-64. PubMed ID: 16533754
    [TBL] [Abstract][Full Text] [Related]  

  • 37. AKT mediates the pro-survival effects of KIT in ovarian cancer cells and is a determinant of sensitivity to imatinib mesylate.
    Shaw TJ; Vanderhyden BC
    Gynecol Oncol; 2007 Apr; 105(1):122-31. PubMed ID: 17169414
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Roles of stem cell factor/c-Kit and effects of Glivec/STI571 in human uveal melanoma cell tumorigenesis.
    Lefevre G; Glotin AL; Calipel A; Mouriaux F; Tran T; Kherrouche Z; Maurage CA; Auclair C; Mascarelli F
    J Biol Chem; 2004 Jul; 279(30):31769-79. PubMed ID: 15145934
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Gastrointestinal stromal tumors.
    Antonescu C
    Curr Top Microbiol Immunol; 2012; 355():41-57. PubMed ID: 22015552
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The phosphodiesterase 4 inhibitor roflumilast augments the Th17-promoting capability of dendritic cells by enhancing IL-23 production, and impairs their T cell stimulatory activity due to elevated IL-10.
    Bros M; Montermann E; Cholaszczyńska A; Reske-Kunz AB
    Int Immunopharmacol; 2016 Jun; 35():174-184. PubMed ID: 27070502
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.